Pancreatic Neoplasms Clinical Trial
Official title:
Apatinib as Second-line Treatment of Advanced Pancreatic Cancer, Phase II Clinical Study of Open Arm
The main research purpose Evaluation of objective response Apatinib second-line treatment of
advanced pancreatic cancer (ORR) and the rate of progression free survival (PFS).
Objective to study the objective and exploratory secondary research To observe the Apatinib
in second line treatment of advanced pancreatic cancer disease control rate (DCR), patients
with overall survival (OS) benefit, treatment effects on quality of life (QOL) score and
drug safety evaluation, To investigate the relationship of apatinib as second-line treatment
of advanced pancreatic cancer and the expression of vascular endothelial growth factor
receptor(VEGFR) in the serum
The purpose of this study is to determine what effects apatinib has on advanced pancreatic
cancer patients after failure of first-line chemotherapy cannot tolerate second-line
chemotherapy or unwilling to receive second-line chemotherapy of pancreatic cancer
patients.To investigate the relationship between apatinib as second-line treatment of
advanced pancreatic cancer and the expression of vascular endothelial growth factor
receptor(VEGFR) in the serum.
This study choose the First Affiliated Hospital of Xi'an JiaoTong University were unable to
tolerate the failure of first-line chemotherapy for second-line chemotherapy or unwilling to
receive second-line chemotherapy of pancreatic cancer patients as the research object, the
clinical data of clinical subjects age and sex, Eastern Cooperative Oncology Group （ECOG）
score, tumor stage, pathological type, pathological grading, giving apatinib treatment,
during the treatment of blood monitoring in patients with CA199 levels, imaging findings,
assessment of tumor related symptoms and adverse events, and the expression of VEGFR in
blood was measured by ELISA method, the curative effect evaluation of the end of the 2 cycle
of treatment, patients with effective evaluation to oral apatinib, through the statistical
analysis of the data of complete remission (CR) or partial remission (PR), the rate of
progression free survival (PFS) expression of CA199 content in serum and serum VEGFR levels
of the relevant indicators,. Explore Apatinib for the curative effect and safety of the
second-line treatment of advanced pancreatic cancer, and to explore the relationship between
the serum VEGF expression level.
;
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04085055 -
Fine Needle Biopsy of Solid Pancreatic Mass Lesions
|
N/A | |
| Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
| Terminated |
NCT00529113 -
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT04809935 -
EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy
|
Phase 4 | |
| Recruiting |
NCT05481476 -
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04652271 -
International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
|
||
| Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
| Completed |
NCT03054987 -
Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction
|
N/A | |
| Completed |
NCT02909530 -
Comparison Between Olympus EZ Shot 3Plus 19G and EZ Shot 2 19G in EUS-guided FNB of Solid Pancreatic Masses
|
N/A | |
| Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
| Completed |
NCT01770405 -
Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
|
N/A | |
| Terminated |
NCT01313416 -
Gemcitabine and CT-011 for Resected Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT01515046 -
Clinical Trial of High-dose Vitamin C for Advanced Pancreatic Cancer
|
Phase 2 | |
| Enrolling by invitation |
NCT01465425 -
Extracolonic Findings on Computed Tomography (CT) Colonography
|
||
| Terminated |
NCT01434459 -
Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin
|
Phase 1 | |
| Completed |
NCT00985777 -
Vitamin E δ-Tocotrienol Administered to Subjects With Resectable Pancreatic Exocrine Neoplasia
|
Phase 1 | |
| Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT00178763 -
Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer
|
Phase 2 | |
| Completed |
NCT00136669 -
Acupuncture For Pancreatic Cancer Pain
|
Phase 3 |